Abstract：
UNASSIGNED: Allergic bronchopulmonary aspergillosis (ABPA) is a lung disease caused by a hypersensitivity reaction to antigens of Aspergillus fumigatus.
UNASSIGNED: The aim of this study was to evaluate the long-term clinical outcomes of omalizumab use in patients with ABPA.
UNASSIGNED: In this retrospective study, 12 patients diagnosed with ABPA and receiving omalizumab for at least 2 years, and 32 patients diagnosed with severe allergic asthma and receiving omalizumab for at least 2 years (control group) were evaluated.
UNASSIGNED: Evaluation was made of a total of 44 participants, comprising 11 (25%) males and 33 (75%) females, who received omalizumab for at least 2 years with the diagnosis of the control group (n = 32) and ABPA (n = 12). The increase in asthma control test (ACT) score after omalizumab was significant at 12 months and at 24 months in patients with ABPA. After omalizumab, the use of oral corticosteroid (OCS), the annual number of asthma attacks and hospitalizations were significantly decreased at 12 months and at 24 months in patients with ABPA. The increase in forced expiratory volume in 1 s (FEV1) (%) and ACT score after omalizumab were significant at 12 months and at 24 months in the control group. After omalizumab, the use of OCS, annual number of asthma attacks and hospitalizations were significantly decreased at 12 months and at 24 months in the control group.
UNASSIGNED: Long-term omalizumab use in patients with ABPA seems to be an effective treatment for improving pulmonary function and reducing asthma exacerbations and hospitalizations.
UNASSIGNED: The aim of this study was to evaluate the long-term clinical outcomes of omalizumab use in patients with ABPA.
UNASSIGNED: In this retrospective study, 12 patients diagnosed with ABPA and receiving omalizumab for at least 2 years, and 32 patients diagnosed with severe allergic asthma and receiving omalizumab for at least 2 years (control group) were evaluated.
UNASSIGNED: Evaluation was made of a total of 44 participants, comprising 11 (25%) males and 33 (75%) females, who received omalizumab for at least 2 years with the diagnosis of the control group (n = 32) and ABPA (n = 12). The increase in asthma control test (ACT) score after omalizumab was significant at 12 months and at 24 months in patients with ABPA. After omalizumab, the use of oral corticosteroid (OCS), the annual number of asthma attacks and hospitalizations were significantly decreased at 12 months and at 24 months in patients with ABPA. The increase in forced expiratory volume in 1 s (FEV1) (%) and ACT score after omalizumab were significant at 12 months and at 24 months in the control group. After omalizumab, the use of OCS, annual number of asthma attacks and hospitalizations were significantly decreased at 12 months and at 24 months in the control group.
UNASSIGNED: Long-term omalizumab use in patients with ABPA seems to be an effective treatment for improving pulmonary function and reducing asthma exacerbations and hospitalizations.
摘要：
简介过敏性支气管肺曲霉病（ABPA）是由对烟曲霉抗原的超敏反应引起的肺部疾病。目的本研究的目的是评估奥马珠单抗在ABPA患者中的长期临床疗效。方法在这项回顾性研究中，12例诊断为ABPA并接受奥马珠单抗至少2年的患者，对32例诊断为重度过敏性哮喘并接受奥马珠单抗治疗至少2年的患者(对照组)进行了评估.结果共对44名参与者进行了评估,包括11名(25%)男性和33名(75%)女性，接受奥马珠单抗治疗至少2年，诊断为对照组（n=32）和ABPA（n=12）。ABPA患者在12个月和24个月时，奥马珠单抗后的哮喘控制测试（ACT）评分显着增加。奥马珠单抗后，使用口服皮质类固醇（OCS），在12个月和24个月时,ABPA患者的年度哮喘发作和住院次数显著减少.对照组在12个月和24个月时，奥马珠单抗后1秒用力呼气量（FEV1）（％）和ACT评分的增加显着。奥马珠单抗后，使用OCS，在12个月和24个月时,对照组的年度哮喘发作和住院次数显著减少.结论在ABPA患者中长期使用奥马珠单抗似乎是改善肺功能和减少哮喘加重和住院的有效治疗方法。
